[go: up one dir, main page]

MA51075A - Procédés et compositions pour traiter des troubles à l'aide de polypeptides de follistatine - Google Patents

Procédés et compositions pour traiter des troubles à l'aide de polypeptides de follistatine

Info

Publication number
MA51075A
MA51075A MA051075A MA51075A MA51075A MA 51075 A MA51075 A MA 51075A MA 051075 A MA051075 A MA 051075A MA 51075 A MA51075 A MA 51075A MA 51075 A MA51075 A MA 51075A
Authority
MA
Morocco
Prior art keywords
compositions
methods
treating disorders
follistatin polypeptides
follistatin
Prior art date
Application number
MA051075A
Other languages
English (en)
Inventor
Asya Grinberg
Ravindra Kumar
Original Assignee
Acceleron Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acceleron Pharma Inc filed Critical Acceleron Pharma Inc
Publication of MA51075A publication Critical patent/MA51075A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702Regulators; Modulating activity
    • C07K14/4703Inhibitors; Suppressors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4707Muscular dystrophy
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06Anabolic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MA051075A 2014-06-04 2015-06-04 Procédés et compositions pour traiter des troubles à l'aide de polypeptides de follistatine MA51075A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462007908P 2014-06-04 2014-06-04

Publications (1)

Publication Number Publication Date
MA51075A true MA51075A (fr) 2020-10-14

Family

ID=54767384

Family Applications (2)

Application Number Title Priority Date Filing Date
MA051074A MA51074A (fr) 2014-06-04 2015-06-04 Procédés et compositions pour traiter des troubles à l'aide de polypeptides de follistatine
MA051075A MA51075A (fr) 2014-06-04 2015-06-04 Procédés et compositions pour traiter des troubles à l'aide de polypeptides de follistatine

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA051074A MA51074A (fr) 2014-06-04 2015-06-04 Procédés et compositions pour traiter des troubles à l'aide de polypeptides de follistatine

Country Status (12)

Country Link
US (2) US10023621B2 (fr)
EP (2) EP3721892B1 (fr)
JP (3) JP6568110B2 (fr)
KR (4) KR20210119546A (fr)
CN (2) CN106795224B (fr)
AU (2) AU2015269333B2 (fr)
BR (1) BR112016028520A2 (fr)
CA (1) CA2950754C (fr)
EA (2) EA202090632A1 (fr)
MA (2) MA51074A (fr)
MX (2) MX382908B (fr)
WO (1) WO2015187977A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201509620SA (en) 2005-11-23 2015-12-30 Acceleron Pharma Inc Activin-actriia antagonists and uses for promoting bone growth
EP3415161A1 (fr) 2008-06-26 2018-12-19 Acceleron Pharma Inc. Utilisation d'un antagoniste actriib pour le traitement de l'anémie
EA201590719A1 (ru) 2013-01-25 2015-12-30 Шир Хьюман Дженетик Терапис, Инк. Фоллистатин в лечении мышечной дистрофии дюшенна
US10010498B2 (en) 2014-06-04 2018-07-03 Acceleron Pharma Inc. Methods for treatment of amyotrophic lateral sclerosis with follistatin fusion proteins
EA202090632A1 (ru) * 2014-06-04 2020-07-31 Акселерон Фарма Инк. Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
BR122023023170A2 (pt) 2014-06-13 2024-02-20 Acceleron Pharma Inc. Uso de um antagonista de actrii no tratamento ou prevenção de úlcera cutânea associada com beta-talassemia
CA2980757A1 (fr) * 2015-03-26 2016-09-29 Acceleron Pharma Inc. Proteines de fusion associees a la follistatine et leurs utilisations
KR20180137487A (ko) * 2016-03-04 2018-12-27 샤이어 휴먼 지네틱 테라피즈 인크. 재조합 폴리스타틴-fc 융합 단백질 및 듀시엔형 근이영양증 치료에서의 용도
US10905766B2 (en) 2017-03-23 2021-02-02 Oregon State University Therapeutic compositions and methods for treatment of muscle wasting diseases
KR101822633B1 (ko) * 2017-08-22 2018-01-26 (주)진셀팜 폴리스타틴 유래 생리활성 펩타이드, 및 이의 용도
WO2019046903A1 (fr) * 2017-09-08 2019-03-14 Baker Heart and Diabetes Institute Procédé thérapeutique pour augmenter la masse musculaire chez un sujet
CN108218985B (zh) * 2017-12-12 2021-04-30 山西农业大学 一种利用特征多肽制备fst蛋白特异性抗体的方法及其应用
EP3765601A1 (fr) * 2018-03-16 2021-01-20 Immusoft Corporation Lymphocytes b génétiquement modifiées pour sécréter de la follistatine et leurs méthodes d'utilisation pour traiter des maladies, des états, des troubles liés à la follistatine et pour améliorer la croissance et la résistance musculaires
JP7183291B2 (ja) * 2018-03-21 2022-12-05 松陽生技股▲分▼有限公司 局部の筋肉増加を促進し、若しくは局部の筋萎縮を抑制又は防止する組成物及び当該組成物を使用して製造された薬物
WO2019191204A1 (fr) * 2018-03-28 2019-10-03 Acceleron Pharma Inc. Polypeptides de follistatine pour le traitement de la contracture musculaire
US20210207135A1 (en) * 2018-05-17 2021-07-08 Housey Pharmaceutical Research Laboratories, L.L.C. Inhibition of follistatin
WO2020046466A1 (fr) * 2018-08-29 2020-03-05 Myos Rens Technology, Inc. Méthodes pour atténuer, inhiber ou inverser une atrophie musculaire par inaction chez le mammifère
AU2023291634A1 (en) 2022-06-15 2025-01-30 UCB Biopharma SRL Follistatin-fc fusion proteins
IL317374A (en) 2022-06-15 2025-02-01 UCB Biopharma SRL Fusion protein for the prevention, treatment or alleviation of kidney disease
WO2024121351A1 (fr) * 2022-12-07 2024-06-13 Lodberg Andreas Composés de liaison à une matrice extracellulaire pour le chargement localisé d'agents thérapeutiques ou diagnostiques

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU597574B2 (en) 1986-03-07 1990-06-07 Massachusetts Institute Of Technology Method for enhancing glycoprotein stability
US5182375A (en) 1987-08-28 1993-01-26 The Salk Institute For Biological Studies DNA encoding follistatin
US5041538A (en) 1987-08-28 1991-08-20 The Salk Institute For Biological Studies Mammalian follistatin
AU660662B2 (en) * 1991-02-08 1995-07-06 Progenics Pharmaceuticals, Inc. CD4-gamma2 and CD4-IgG2 chimeras
JPH08501314A (ja) 1992-09-16 1996-02-13 ジェネンテク,インコーポレイテッド Hgfによる肝臓障害に対する保護
US6686198B1 (en) 1993-10-14 2004-02-03 President And Fellows Of Harvard College Method of inducing and maintaining neuronal cells
EP0726948B1 (fr) 1993-10-14 2007-02-28 President And Fellows Of Harvard College Procede d'induction et de maintien de cellules neuronales
US5541087A (en) 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US5545616A (en) 1994-09-22 1996-08-13 Genentech, Inc. Method for predicting and/or preventing preterm labor
GB2306481A (en) 1995-10-21 1997-05-07 Univ Manchester Pharmaceutical comprising a stimulator of activin and/or inhibin
US6891082B2 (en) 1997-08-01 2005-05-10 The Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a truncated activintype II receptor
US6656475B1 (en) 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
WO1999006559A1 (fr) 1997-08-01 1999-02-11 The Johns Hopkins University School Of Medicine Procedes d'identification des recepteurs des facteurs de differenciation de la croissance
US6004937A (en) 1998-03-09 1999-12-21 Genetics Institute, Inc. Use of follistatin to modulate growth and differentiation factor 8 [GDF-8] and bone morphogenic protein 11 [BMP-11]
JP2003517580A (ja) 1999-01-21 2003-05-27 メタモーフイクス・インコーポレーテツド 増殖分化因子インヒビター及びそれらの用途
AU777783B2 (en) 1999-04-19 2004-10-28 Kyowa Hakko Kogyo Co. Ltd. Proliferation inhibitor for androgen-independent tumor
WO2001009368A1 (fr) 1999-07-30 2001-02-08 The General Hospital Corporation Antagonistes de la follistatine
JP4487376B2 (ja) 2000-03-31 2010-06-23 味の素株式会社 腎疾患治療剤
AUPR638101A0 (en) 2001-07-13 2001-08-09 Bioa Pty Limited Composition and method for treatment of disease
CA2476654A1 (fr) 2002-02-21 2003-09-04 Wyeth Domaine follistatine contenant des proteines
WO2003072715A2 (fr) 2002-02-21 2003-09-04 Wyeth Proteine contenant un domaine de follistatine
CN1993048A (zh) * 2002-02-21 2007-07-04 惠氏公司 包含促滤泡素抑制素结构域的蛋白质
WO2004082710A1 (fr) 2003-03-21 2004-09-30 Lorantis Limited Traitement de maladies allergiques utilisant un modulateur de la voie de signalisation notch
CN1829532A (zh) 2003-06-02 2006-09-06 惠氏公司 肌肉抑制素(gdf8)抑制剂和皮质类固醇联合用于治疗神经肌肉紊乱的用途
US20070135336A1 (en) 2003-09-15 2007-06-14 De Kretser David Follistatin isoforms and uses thereof
WO2005033134A2 (fr) * 2003-09-30 2005-04-14 Regeneron Pharmaceuticals, Inc. Therapeutique et utilisations d'une proteine secretee
US8920806B2 (en) 2003-10-06 2014-12-30 Paranta Biosciences Limited Method of modulating inflammatory response by downregulation of activin
JP4688483B2 (ja) 2004-04-15 2011-05-25 株式会社テクノネットワーク四国 フォリスタチン変異体ポリペプチド
AU2005266875B2 (en) * 2004-07-23 2012-07-26 Acceleron Pharma Inc. ActRII receptor polypeptides, methods and compositions
AU2005272646A1 (en) 2004-08-12 2006-02-23 Wyeth Combination therapy for diabetes, obesity, and cardiovascular diseases using GDF-8 inhibitors
NZ538097A (en) 2005-02-07 2006-07-28 Ovita Ltd Method and compositions for improving wound healing
AU2006283725B2 (en) 2005-08-19 2012-02-16 The Trustees Of The University Of Pennsylvania Antagonist antibodies against GDF-8 and uses in treatment of ALS and other GDF-8-associated disorders
AU2006321906C1 (en) * 2005-12-06 2014-01-16 Amgen Inc. Uses of myostatin antagonists
WO2008030367A2 (fr) 2006-09-01 2008-03-13 The General Hospital Corporation Inhibiteurs sélectifs de la myostatine
ES2569365T3 (es) 2006-11-29 2016-05-10 Nationwide Children's Hospital Inhibición de miostatina para la potenciación de músculo y/o la mejora de la función muscular
US20100028332A1 (en) 2006-12-18 2010-02-04 Acceleron Pharma Inc. Antagonists of actriib and uses for increasing red blood cell levels
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
JP5415279B2 (ja) 2006-12-18 2014-02-12 アクセルロン ファーマ, インコーポレイテッド アクチビン−ActRIIアンタゴニストおよび赤血球レベルを増加させるためのその使用
AU2009204501B2 (en) 2008-01-07 2015-02-12 Amgen Inc. Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects
EP3415161A1 (fr) 2008-06-26 2018-12-19 Acceleron Pharma Inc. Utilisation d'un antagoniste actriib pour le traitement de l'anémie
EP2318028B1 (fr) * 2008-06-26 2020-02-19 Acceleron Pharma Inc. Antagonistes solubles d'activine-actriia et utilisations pour augmenter les taux d'érythrocytes
KR20200086378A (ko) * 2009-09-09 2020-07-16 악셀레론 파마 인코포레이티드 ActRIIb 길항제들와 이의 투약 및 용도
JP5813114B2 (ja) * 2010-08-25 2015-11-17 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Il−18r1に対する抗体およびその使用
JP6167040B2 (ja) 2010-11-05 2017-07-19 ザイムワークス,インコーポレイテッド Fcドメイン中に突然変異を有する、安定したヘテロ二量体抗体の設計
DE18200782T1 (de) * 2012-04-02 2021-10-21 Modernatx, Inc. Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen
CA2867202A1 (fr) 2012-05-17 2013-11-21 Paranta Biosciences Limited Procede de traitement et agents utiles pour celui-ci
WO2014003553A1 (fr) * 2012-06-27 2014-01-03 Arthrogen B.V. Combinaison de traitement d'un trouble inflammatoire
EA201590719A1 (ru) * 2013-01-25 2015-12-30 Шир Хьюман Дженетик Терапис, Инк. Фоллистатин в лечении мышечной дистрофии дюшенна
WO2014187807A1 (fr) * 2013-05-21 2014-11-27 Arcarios B.V. Dérivés de follistatine
US10010498B2 (en) 2014-06-04 2018-07-03 Acceleron Pharma Inc. Methods for treatment of amyotrophic lateral sclerosis with follistatin fusion proteins
EA202090632A1 (ru) * 2014-06-04 2020-07-31 Акселерон Фарма Инк. Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
CA2980757A1 (fr) * 2015-03-26 2016-09-29 Acceleron Pharma Inc. Proteines de fusion associees a la follistatine et leurs utilisations
MX2019013523A (es) 2017-05-12 2020-07-14 Takeda Pharmaceuticals Co Proteínas de fusión de folistatina-fc recombinante y uso en el tratamiento de la distrofia muscular de duchenne.

Also Published As

Publication number Publication date
KR102132144B1 (ko) 2020-07-09
MX2021006017A (es) 2021-07-06
KR20200017548A (ko) 2020-02-18
US20180340013A1 (en) 2018-11-29
KR102305109B1 (ko) 2021-09-27
CA2950754C (fr) 2021-10-26
EA035455B1 (ru) 2020-06-18
MX382908B (es) 2025-03-13
US10023621B2 (en) 2018-07-17
JP2019203017A (ja) 2019-11-28
MA51074A (fr) 2020-10-14
AU2015269333A1 (en) 2016-12-15
KR102077286B1 (ko) 2020-02-13
CN113583104A (zh) 2021-11-02
CA2950754A1 (fr) 2015-12-10
EP3152237A1 (fr) 2017-04-12
US20160185836A1 (en) 2016-06-30
KR20200084064A (ko) 2020-07-09
JP2021095416A (ja) 2021-06-24
EA202090632A1 (ru) 2020-07-31
JP6568110B2 (ja) 2019-08-28
EP3721892B1 (fr) 2024-05-22
EA201692529A1 (ru) 2017-05-31
MX2016015868A (es) 2017-04-05
CN106795224A (zh) 2017-05-31
KR20170005891A (ko) 2017-01-16
JP2017518303A (ja) 2017-07-06
AU2020210315A1 (en) 2020-08-27
AU2015269333B2 (en) 2020-05-07
JP6856716B2 (ja) 2021-04-07
EP3152237B1 (fr) 2020-04-01
BR112016028520A2 (pt) 2017-10-24
CN106795224B (zh) 2021-05-18
US10954279B2 (en) 2021-03-23
KR20210119546A (ko) 2021-10-05
EP3152237A4 (fr) 2017-11-01
WO2015187977A1 (fr) 2015-12-10
EP3721892A1 (fr) 2020-10-14

Similar Documents

Publication Publication Date Title
MA51075A (fr) Procédés et compositions pour traiter des troubles à l'aide de polypeptides de follistatine
IL291533A (en) Compounds and preparations including them for the treatment of diseases of the central nervous system
EP3364993A4 (fr) Procédés pour traiter le syndrome d'angelman et des troubles associés
SMT202000414T1 (it) Composizioni e metodi per trattare disturbi del snc
SMT202000276T1 (it) Composizioni e metodi per trattare disturbi del snc
EP3319976A4 (fr) Compositions et procédés pour traiter des maladies pulmonaires et des lésions pulmonaires
SI3250210T1 (sl) Sestavki in metode za zdravljenje CNS motenj
EP3353278A4 (fr) Préparation d'échantillons pour des types d'échantillons compliqués
EP3390642A4 (fr) Compositions et procédés pour le traitement de rétinite pigmentaire 18 et de rétinite pigmentaire 13
MA44886A (fr) Compositions et méthode pour traiter des troubles acide-base
EP3180022A4 (fr) Cassette d'expression améliorée pour le conditionnement et l'expression de variantes du facteur viii pour le traitement des troubles de l'hémostase
EP3703706A4 (fr) Compositions et méthode pour traiter des troubles acide-base
EP3291693A4 (fr) Régime alimentaire imitant et favorisant le jeûne pour le traitement de l'hypertension et des troubles lipidiques
GB201411241D0 (en) Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders
EP3358929A4 (fr) Procédés et appareils pour le traitement d'une matière agricole
GB201401086D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
EP3204028A4 (fr) Composition synergique pour l'arthrose
EP3551162C0 (fr) Composition appropriée pour le nettoyage
FR3020758B1 (fr) Composition pour ameliorer l'hygiene buco-dentaire
MA44747A (fr) Méthodes et compositions pour le traitement de troubles associés à une accumulation du glycogène cytoplasmique
EP3377073A4 (fr) Méthodes et compositions pour traiter des troubles et des maladies à l'aide de la protéine de survie des motoneurones (smn)
EP3294339A4 (fr) Méthodes et compositions pour le traitement de l'arthrite
EP3328428A4 (fr) Procédés et compositions pour le traitement de maladies et de troubles immunomodulateurs
FR3040122B1 (fr) Casier formant nasse pour des mollusques
EP3436021A4 (fr) Compositions et méthodes pour traiter des troubles du déficit de l'attention